The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Dolzhansky O.V.

Petrovsky Russian Research Center for Surgery, Moscow, Russia

Pal'tseva E.M.

Laboratoriia élektronnoĭ mikroskopii i immunogistokhimii Tsentralizovannogo patologoanatomicheskogo otdeleniia GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova" Minzdravsotsrazvitiia Rossii

Bukaeva A.A.

Academician B.V. Petrovsky Russian Research Center of Surgery, Moscow, Russia

Zakliaz'minskaia E.V.

FGBU RNTsKh im. akad. B.V. Petrovskogo RAMN

Solovyova S.E.

Department of Heart Valve Surgery Petrovsky Russian Research Center for Surgery, Moscow, Russia

Fedorov D.N.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

The morphological and molecular genetic characteristics of sarcomatoid chromophobe renal cell carcinoma

Authors:

Dolzhansky O.V., Pal'tseva E.M., Bukaeva A.A., Zakliaz'minskaia E.V., Solovyova S.E., Fedorov D.N.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2018;80(4): 39‑46

DOI: 10.17116/patol201880439

Read: 8441 times

Download PDF (RU)
Contact the author
Table of contents

THE MORPHOLOGICAL AND MOLECULAR GENETIC CHARACTERISTICS OF SARCOMATOID CHROMOPHOBE RENAL CELL CARCINOMA
THE MORPHOLOGICAL AND MOLECULAR GENETIC CHARACTERISTICS OF SARCOMATOID CHROMOPHOBE RENAL CELL CARCINOMA

To cite this article:

Dolzhansky OV, Pal'tseva EM, Bukaeva AA, Zakliaz'minskaia EV, Solovyova SE, Fedorov DN. The morphological and molecular genetic characteristics of sarcomatoid chromophobe renal cell carcinoma. Russian Journal of Archive of Pathology. 2018;80(4):39‑46. (In Russ.)
https://doi.org/10.17116/patol201880439

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Classification of non-small cell lung cancer acco­rding to the WHO 2021: from morphology to personalized therapy. Russian Journal of Archive of Pathology. 2026;(1):60-67
The features of cancer-associated fibroblasts as components of tumor stroma in bladder cancer. Russian Journal of Archive of Pathology. 2026;(2):87-93
Clinical significance of gene­tic muta­tions in epithelial tumors of the thymus. P.A. Herzen Journal of Onco­logy. 2025;(2):70-75
A clinical case of fami­lial alopecia areata in combination with immune pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):304-312
Meta­stasis of thyroid cancer to retroperitoneal lymph nodes and breast. P.A. Herzen Journal of Onco­logy. 2025;(4):82-85
Resu­lts of testing an antioxidant gel film for the prevention and treatment of palmar-plantar syndrome in cancer patients. P.A. Herzen Journal of Onco­logy. 2025;(5):59-63
Predictors of arrhythmia and adve­rse outcomes in cancer patients during anti­tumor treatment. Russian Journal of Preventive Medi­cine. 2025;(11):86-93
Prognostically unfa­vorable types of breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(6):78-82
Rela­tionship between inte­stinal microbiota and psoriasis pathogenesis. Russian Journal of Clinical Dermatology and Vene­reology. 2026;(1):15-22
Biopsy in the treatment of children with diffuse brainstem tumors. Burdenko's Journal of Neurosurgery. 2026;(2):29-36
Abstract:

The paper describes a case of chromophobe renal cell carcinoma growing into the muscular layer of the descending colon and with metastases in 4 lymph nodes of paranephral tissue in a 66-year-old woman. The tumor had a zonal structure with an alternation of epithelioid and sarcomatoid structural sites and with the signs of grades I, II and III according to the grading system by Paner and et al. (2010). The sarcomatoid renal component occupied about 70.0% of the tumor. There was a pronounced immunohistochemical reaction with VEGF-A (5 scores), a high Ki-67 proliferation index (70%), and a large number of tumor cells with nuclear p53 expression (85%) in the areas with minimal differentiation and sarcomatoid elements (Grade III). These signs can serve as criteria for the aggressive behavior of the tumor. A large volume of the sarcomatoid carcinoma component and a strong reaction with VEGF-A are indications for targeted therapy with anti-VEGF drugs.

Keywords:

chromophobe renal cell carcinoma
sarcomatoid differentiation
VEGF-A
targeted therapy

Authors:

Dolzhansky O.V.

Petrovsky Russian Research Center for Surgery, Moscow, Russia

Pal'tseva E.M.

Laboratoriia élektronnoĭ mikroskopii i immunogistokhimii Tsentralizovannogo patologoanatomicheskogo otdeleniia GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova" Minzdravsotsrazvitiia Rossii

Bukaeva A.A.

Academician B.V. Petrovsky Russian Research Center of Surgery, Moscow, Russia

Zakliaz'minskaia E.V.

FGBU RNTsKh im. akad. B.V. Petrovskogo RAMN

Solovyova S.E.

Department of Heart Valve Surgery Petrovsky Russian Research Center for Surgery, Moscow, Russia

Fedorov D.N.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Close metadata

References:

  1. Quiroga-Garza G, Khurana H, Shen S, Ayala AG, Ro JY. Sarcomatoid chromophobe renal cell carcinoma with heterologous sarcomatoid elements. A case report and review of the literature. Arch Pathol Lab Med. 2009;133(11):1857-1860. https://doi.org/10.1043/1543-2165-133.11.1857
  2. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol.2001;25(3):275-284. https://www.ncbi.nlm.nih.gov/pubmed/?term=Sarcomatoid+differentiation+in+renal+cell+carcinoma%3A+a+study+of+101+cases
  3. Ebru T, Fulya OP, Hakan A, Vuslat YC, Necdet S, Nuray C, Filiz O. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma. Int Braz J Urol. 2017; 43(3):440-454. https://doi.org/10.1590/S1677-5538.IBJU.2015.0521
  4. Osman WM, Youssef NS. Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(7):8165-8177. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555713/
  5. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK,Tannir NM. Systemic therapy for metastatic non-clear cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am. 2011;25(4):853-869. https://doi.org/10.1016/j.hoc.2011.05.003
  6. Yang Y, Vocke CD, Ricketts CJ, Wei D, Padilla-Nash HM, Lang M, Sourbier C, Killian JK, Boyle SL, Worrell R, Meltzer PS, Ried T, Merino MJ, Metwalli AR, Linehan WM. Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes Cancer. 2017;56(10):719-729. https://doi.org/10.1002/gcc.22476
  7. Zhang Z, Min J, Yu D, Shi H, Xie D. Renal collision tumour of papillary cell carcinoma and chromophobe cell carcinoma with sarcomatoid transformation: A case report and review of the literature. Can Urol Assoc J. 2014;8(7-8):E536-E539. https://doi.org/10.5489/cuaj.1811
  8. Bostwick DG, Cheng L, eds. Urologic surgical pathology. 3th ed. Philadelphia: Elsevier; 2014.
  9. Tanaka Y, Koie T, Hatakeyama S, Hashimoto Y, Ohyama C. Chromophobe renal cell carcinoma with concomitant sarcomatoid transformation and osseous metaplasia: a case report. BMC Urol. 2013;13:72. https://doi.org/10.1186/1471-2490-13-72
  10. Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer. 2010;116(3): 616-624. https://doi.org/10.1002/cncr.2476819998348
  11. Lager DJ, Abrahams NA, eds. Practical renal pathology: a diagnostic approach. Philadelphia: Elsevier; 2013.
  12. Zhang T, Gong J, Maia MC, Pal SK. Systemic therapy for non-clear cell renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:337-342. https://doi.org/10.14694/EDBK_175572
  13. Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist. 2012;17(1):46-54. https://doi.org/10.1634/theoncologist.2011-0227
  14. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res. 1995;55(3):658-662. https://www.ncbi.nlm.nih.gov/pubmed/?term=7834636
  15. Cserni G, Kovács BR, Tarján M, Sápi Z, Domján Z, Szabó Z. Sarcomatoid renal cell carcinoma with foci of chromophobe carcinoma. Pathol Oncol Res. 2002;8(2):142-144.
  16. Wu J, Joseph SO, Muggia FM. Targeted therapy: its status and promise in selected solid tumors part I: areas of major impact. Oncology (Williston Park). 2012;26(10):936-943. https://www. ncbi.nlm.nih.gov/pubmed/?term=23176005
  17. Kobayashi N, Suzuki K, Murakami H, Kagawa E, Aoki I, Nagashima Y. Chromophobe renal cell carcinoma with sarcomatoid transformation in a dog. J Vet Diagn Invest. 2010;22(6):983-987. https://doi.org/10.1177/104063871002200624
  18. Martignoni G, Pea M, Brunelli M, Chilosi M, Zamó A, Bertaso M, Cossu-Rocca P, Eble JN, Mikuz G, Puppa G, Badoual C, Ficarra V, Novella G, Bonetti F. CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol. 2004;17(12): 1455-1463. https://doi.org/10.1038/modpathol.3800236
  19. Paner GP, Amin MB, Alvarado-Cabrero I, Young AN, Stricker HJ, Moch H, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol. 2010;34(9):1233-1240. https://doi.org/10.1097/PAS.0b013e3181e96f2a
  20. Moskvina LV, Andreeva YuYu, Mal’kov PG, Frank GA. New approaches to the classification, grading, and prognosis of renal cell carcinoma. Arkhiv patologi. 2014;76(2):60-70. (In Russ.) https: //www. mediasphera.ru /issues /arkhiv-patologii/2014/2/downloads/ru/030004-19552014214
  21. Nefedova NA, Davydova SYu. The role of vascular endothelial growth factor and hypoxia-inducible factor in tumor׳s angiogenesis. Sovremennye problemy nauki i obrazovaniya. 2015;3:51-64. (In Russ.) https://science-education. ru/ru/ article/ view?id=17924
  22. Varlamov AV, Pal’tseva EM, Sekacheva MI, Skipenko OG, Fedorov DN. Impact of preoperative drug therapy on the expression of angiogenesis markers in colorectal liver metastases. Arkhiv patologii. 2017;79(1):36-42. (In Russ.) https://doi.org/10.17116/patol201779136-42
  23. Song SH, Jeong IG, You D, Hong JH, Hong B, Song C, Jung WY, Cho YM, Ahn H, Kim CS. VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in nonmetastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients. Int J Clin Exp Pathol. 2014;7(11):7681-7689. https://www. ncbi. nlm. nih. Gov /pubmed /?term=VEGF%2FVE GFR2+and+PDGF-B%2FPDGFR-% CE% B2+ expression+in+ non-metastatic +renal +cellcarcinoma %3Aa+retrospective+ study+in+1%2C091+consecutive+patients
  24. Minardi D, Santoni M, Lucarini G, Mazzucchelli R, Burattini L, Conti A, Bianconi M, Scartozzi M, Milanese G, Primio RD, Montironi R, Cascinu S, Muzzonigro G. Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. Urol Oncol. 2015;33(3):113. e1-113.e7. https://doi.org/10.1016/j.urolonc.2014.06.014
  25. Stubbs C, Bardoli AD, Afshar M, Pirrie S, Miscoria M, Wheeley I, Porfiri E. A study of angiogenesis markers in patients with renal cell carcinoma undergoing therapy with sunitinib. Anticancer Res. 2017;37(1):253-259. https://doi.org/10.21873/anticanres.11315
  26. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307. https://doi.org/10.1038/nature10144
  27. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015;121(19):3435-3443. https://doi.org/10.1002/cncr.29503
  28. Saylor PJ, Michaelson MD. New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw. 2009;7(6):645-656. https://www.ncbi.nlm.nih.gov/pubmed/?term=19555586
  29. Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bähr O, Mäder L, Goeppert B, Machein M, Seifert V, Steinbach JP, Plate KH, Harter PN, Mittelbronn M. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol. 2016;18(2):173-183. https://doi.org/10.1093/neuonc/nov288
  30. Desar IM, Stillebroer AB, Oosterwijk E, Leenders WP, van Herpen CM, van der Graaf WT, Boerman OC, Mulders PF, Oyen WJ. 111 In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med. 2010;51(11):1707-1715. https://doi.org/10.2967/jnumed.110.07803020956472
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.